Monday, November 16, 2026
Novavax shots to be given out in Taiwan, health agency says
The island's health authority stated that doses of the Novavax vaccine are being handed out. The notice concerns the supply of those shots.
Saturday, November 7, 2026
B. Riley Sets $16 Target for Novavax
B. Riley now lists a $16 target for Novavax. The headline offers no further details on the rating or the reasoning behind the figure.
Friday, November 6, 2026
B. Riley Securities keeps Buy rating on Novavax, cuts price target to $16
B. Riley Securities repeated its Buy rating on Novavax while reducing its price target to $16. The note reflects the firm's updated view on the stock.
Thursday, November 5, 2026
Novavax posts Q3 2026 results and business updates
The company shared its quarterly figures for the period ending in 2026's third quarter, along with operational news. The release covers its recent performance and business developments.
Novavax to shrink operating footprint by over 50% via building and lab consolidation
Novavax is consolidating its buildings and laboratories, cutting its operating footprint by more than half. The company also expects to lower total spending further and meet its 2028 efficiency goal, with staffing projected at under half of Q1 2026 levels.
Form 8-K tells shareholders about important events such as deals, leadership changes or results.
Novavax lifts FY2026 sales guidance to $385M-$415M from $235M-$275M
Novavax raised its full-year 2026 sales forecast to a range of $385 million to $415 million, up from its prior $235 million to $275 million range. The new midpoint sits above the $380.285 million analyst estimate.
Novavax posts smaller quarterly loss than expected, revenue tops forecast
The vaccine maker's third-quarter loss came in at 19 cents a share, narrower than the 36 cents analysts expected. Revenue of $68.298 million also came in above the $50.430 million estimate.
Thursday, October 29, 2026
TD Cowen lifts Novavax price target to $11
TD Cowen raised its price target on Novavax to $11. The change is an analyst update on the vaccine maker's stock.
Sanofi pays Novavax $125M under existing agreement
Novavax said it received a $125 million payout tied to a prior arrangement with Sanofi. The money reflects a milestone being met under that deal.
Novavax receives $125M milestone payment as Sanofi begins Phase 3 combo vaccine study
Sanofi has started a Phase 3 trial of an influenza-COVID-19 combination vaccine using Novavax's Nuvaxovid. The study start triggers a $125 million milestone payment to Novavax.
Wednesday, October 28, 2026
Cantor Fitzgerald keeps Buy rating on Novavax
Cantor Fitzgerald repeated its Buy rating on Novavax. The headline gives no new price target or other details.
Monday, October 19, 2026
Top Novavax investor exits activist role after $32.6M share sale
A large holder of Novavax stock sold $32.6 million in shares and has stopped its activist campaign at the company. The move ends that investor's push for changes.
Friday, October 16, 2026
Shah Capital lowers Novavax holding to 6.39% after 2.87M-share sale at $11.35 average
Shah Capital sold 2.87 million Novavax shares at an average of $11.35 each, leaving it with a 6.39% position. The firm also moved its holdings into a family office structure.
Shah Capital Ends SEC Adviser Registration, Shifts Novavax Stance
The firm is pulling its investment adviser registration with the SEC as of Oct. 16. It also said it no longer seeks to influence control at Novavax and will use Schedule 13G filings going forward.
Thursday, October 15, 2026
Citigroup keeps Sell rating on Novavax, lifts target to $8
Citigroup reiterated its Sell rating on Novavax while raising its price target to $8. The update reflects the analyst's latest view on the stock.
Friday, October 9, 2026
NIH vaccine initiative sparks rally in biotech stocks
The National Institutes of Health has launched a vaccine initiative focused on cancer. The announcement lifted shares of biotechnology companies.
Report: NIH to Prioritize Cancer Vaccine Research
A report says the National Institutes of Health plans to make cancer vaccines a major research focus. The move signals a shift in federal funding priorities toward preventive and therapeutic cancer shots.
Wednesday, October 7, 2026
Novavax holds Q2 2026 earnings conference call
Novavax discussed its second-quarter 2026 financial results during an earnings conference call. A transcript of the call is available.
Tuesday, October 6, 2026
Novavax shares fall, possibly giving back recent gains tied to Russia plague reports
Novavax stock moved lower, potentially reversing part of a recent climb linked to a suspected pneumonic plague outbreak in Russia. The headline offers no confirmed reason for the decline.
Moderna, Vaxcyte and Novavax draw after-hours attention amid Russia plague reports
Reports of suspected pneumonic plague in Russia are drawing attention to vaccine makers Moderna, Vaxcyte and Novavax in after-hours trading. The headline gives no confirmed case count or company statements.
Monday, October 5, 2026
Plague Concern in Russia Puts Pressure on Bets Against Novavax
Fears tied to a plague situation in Russia are making short positions in Novavax uncomfortable, according to the report. No company announcement or confirmed development is described.
Friday, August 28, 2026
Novavax partners gain approvals for Nuvaxovid XFG variant formulation
Novavax said its partners have received approvals for a Nuvaxovid formulation designed to target the SARS-CoV-2 XFG variant. The clearances cover the updated version of the vaccine.
Frequently asked questions
What is the latest news on NVAX?
Nov 16, 2026: Novavax shots to be given out in Taiwan, health agency says (Fiscal.ai) · Nov 7, 2026: B. Riley Sets $16 Target for Novavax (Fiscal.ai) · Nov 6, 2026: B. Riley Securities keeps Buy rating on Novavax, cuts price target to $16 (Benzinga)
What has NVAX filed with the SEC recently?
Nov 5, 2026: Novavax Inc filed a report on a major company event (Form 8-K)
Get NVAX news as it happens
Every headline, SEC filing and analyst action for NVAX on your live chart, with important news marked and alerts when it matters.
Try SEPT Free